Description of the characteristics included in the cluster analysis at EGEA2 according to each never asthmatics (NA) endotype
| NA1 (n=489) | NA2 (n=177) | P value | |
| Age, year | 46.3 (15.5) | 47.8 (16.6) | <0.0001 |
| Sex, women | 262 (53.6%) | 109 (61.6%) | 0.07 |
| Smoking habits | 0.005 | ||
| Non-smokers | 249 (50.9%) | 82 (46.3%) | |
| Ex-smokers | 152 (31.1%) | 43 (24.3%) | |
| Smokers | 88 (18.0%) | 52 (29.4%) | |
| Body mass index, kg/m2 | 24.3 (3.82) | 25.4 (4.39) | 0.002 |
| FEV1 % predicted | 108 (16.0) | 105 (17.4) | 0.04 |
| FVC % predicted | 113 (17.5) | 111 (17.7) | 0.13 |
| Shortness of breath and wheezing (last 12 months) | 2 (0.41%) | 36 (20.3%) | <0.0001 |
| Attacks of breathlessness at rest (last 12 months) | 3 (0.61%) | 15 (8.47%) | <0.0001 |
| Attacks of breathlessness following strenuous activity, (last 12 months) | 104 (21.3%) | 76 (42.9%) | <0.0001 |
| Nocturnal symptoms (last 12 months) | |||
| Cough | 103 (21.14%) | 74 (41.8%) | <0.0001 |
| Chest tightness | 2 (0.41%) | 8 (4.52%) | 0.0006 |
| Shortness of breath | 51 (10.4%) | 32 (18.1%) | 0.008 |
| Inhaled corticosteroids (last 12 months) | 1 (0.20%) | 19 (10.7%) | <0.0001 |
| Chronic cough | 1 (0.20%) | 32 (18.1%) | <0.0001 |
| Chronic phlegm | 0 (0%) | 28 (15.8%) | <0.0001 |
| Dyspnoea grade 3 | 4 (0.82%) | 36 (20.3%) | <0.0001 |
| Skin prick test positivity | 175 (35.8%) | 62 (35.0%) | 0.9 |
| Rhinitis (last 12 months) | 84 (17.2%) | 50 (28.2%) | 0.002 |
| Eczema (ever) | 133 (27.2%) | 47 (26.6%) | 0.9 |
| Total IgE, IU/ml, GM (Q1–Q3) | 42.0 (16.4–107) | 52.6 (16.4–135) | 0.07 |
| White blood cell counts | |||
| Eosinophils/mm3 | 156 (108) | 180 (139) | 0.04 |
| Neutrophils/mm3 | 3907 (1269) | 4150 (1488) | 0.02 |
| Fluorescent oxidation products, RFU/mL, GM (Q1–Q3) | 94.0 (81.4–108) | 96.6 (82.1–109) | 0.16 |
Data are means (SD) or n (%) unless otherwise stated.
Dyspnoea grade 3 was defined according to the Medical Research Council scale.
Skin Prick Test positivity was defined by a mean weal diameter ≥3 mm than the negative control for at least one of 12 aeroallergens.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GM, geometric mean; (Q1–Q3), first and third quartiles; RFU, relative fluorescence intensity.